Please enter the email address you used to register, then we will send you a link to choose a new password
Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the...
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.12) per share. This is a 76 percent increase over losses of $(0.50) p...
Nanobiotix reported updated Phase 1 trial data for JNJ-1900 in head and neck cancer, showing strong disease control and surviva...
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïv...
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc....
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...
Nanobiotix reported melanoma study data showing JNJ-1900 delivered 47.4% response rate, 78.9% disease control, and 14.6 months ...